Esperion Theraptc Cm (ESPR) 16.90 $ESPR Looking Into

New Post Public Reply Private Reply Replies (0) Message Board

Jun 24, 2016 at 12:09 AM

Esperion Theraptc Cm (ESPR) 16.90 $ESPR

Looking Into Biotech's Crystal Ball
ACCESSWIRE - Thu May 19, 3:35PM CDT
LAS VEGAS, NV / ACCESSWIRE / May 19, 2016 / While biotech investing is riddled with risk it is also ripe with reward. One way we can mitigate risk in this rough and tumble sector that has made millionaires of many and bankrupted some is to pay attention to subtext and follow the company's true progress. Especially when dealing with development stage biotechs.
ESPR: 16.90 (+0.96)

Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 7:05AM CDT
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C, today provided bempedoic acid (ETC-1002) development program updates and financial results for the first quarter ended March 31, 2016.
ESPR: 16.90 (+0.96)

Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 16.90 (+0.96), CMRX: 3.79 (+0.06), GERN: 2.75 (+0.08), CYTX: 2.00 (-0.01), CLDX: 4.57 (+0.12), SGMO: 5.92 (+0.30), PTCT: 7.00 (+0.40), ATHX: 2.00 (+0.05), MNKD: 1.24 (+0.06)

IRRAS AB Appoints Anders P. Wiklund to its Board of Directors
PR Newswire Europe - Wed Mar 23, 7:01AM CDT
- Mr. Wiklund is a well recognized and seasoned healthcare executive
ESPR: 16.90 (+0.96)

Biotech Trade Alert
ACCESSWIRE - Tue Mar 15, 11:50AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 15, 2016 / We are issuing an immediate trade alert on Endonovo Therapeutics (OTCQB: ENDV) and a few other biotech companies.
ESPR: 16.90 (+0.96), VCEL: 2.29 (+0.06), SGMO: 5.92 (+0.30), ZYNE: 7.77 (+0.49)

INVESTOR DEADLINE: Law Office of Brodsky & Smith, LLC Announces Investigation of Esperion Therapeutics, Inc.
BusinessWire - Fri Mar 11, 8:35PM CST
Law Office of Brodsky & Smith, LLC announces an investigation of Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(Nasdaq: ESPR) for potential violations of federal securities laws and breaches of the Esperion Board's fiduciary duties.
ESPR: 16.90 (+0.96)

March 14 Deadline Alert: Law Offices of Howard G. Smith Reminds Esperion Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline
BusinessWire - Fri Mar 11, 8:30AM CST
Law Offices of Howard G. Smith reminds investors of the upcoming March 14, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(NASDAQ: ESPR) securities between August 18, 2015 and September 28, 2015, inclusive (the "Class Period"

. Investors who suffered losses on their investment in Esperion securities are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights.
ESPR: 16.90 (+0.96)

Scott + Scott, LLP Notifies Investors That Monday, March 14, 2016 is Last Day to File Lead Plaintiff Papers in Esperion Therapeutics (ESPR) Securities Case
GlobeNewswire - Wed Mar 09, 7:45PM CST
Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics, Inc. (ESPR). Esperion investors are encouraged to contact Scott + Scott at (866) 326-5057 or email gjohnson@scott-scott.com to discuss their legal rights.
ESPR: 16.90 (+0.96)

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Esperion Therapeutics, Inc. (ESPR) and Lead Plaintiff Deadline: March 14, 2016
ACCESSWIRE - Wed Mar 09, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / March 11, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors of class action against Esperion Therapeutics, Inc. (Esperion or "the Company"

(Nasdaq: ESPR) and certain of its officers. The class action was filed in the United States District Court for the Eastern District of Michigan on behalf of a class consisting of all persons or entities who purchased shares from August 18, 2015 through September 28, 2015, all dates inclusive (the "Class Period"

. Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
ESPR: 16.90 (+0.96)

Esperion Therapeutics to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Tue Mar 08, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C, today announced Tim M. Mayleben, president and chief executive officer, will present at the Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 15, 2016 at 8:30 A.M. Eastern Time.
ESPR: 16.90 (+0.96)

Glancy Prongay & Murray LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit against Esperion Therapeutics, Inc.
BusinessWire - Tue Mar 08, 9:30AM CST
Glancy Prongay & Murray LLP ("GPM"

reminds investors that a class action complaint has been filed on behalf of a class of investors who purchased Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(Nasdaq: ESPR) securities between August 18, 2015 and September 28, 2015, inclusive (the "Class Period"

. Esperion investors have until March 14, 2016 to file a lead plaintiff motion. Investors are encouraged to contact GPM to discuss their legal rights.
ESPR: 16.90 (+0.96)

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 14, 2016 - ESPR
PR Newswire - Tue Mar 08, 8:52AM CST
The following statement is being issued by Levi & Korsinsky, LLP:
ESPR: 16.90 (+0.96)

Scott + Scott, LLP Notifies Investors of Monday, March 14, 2016 Deadline in Esperion Therapeutics (ESPR) Securities Case
BusinessWire - Mon Mar 07, 10:39AM CST
Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics, Inc. (ESPR). Esperion investors are encouraged to contact Scott + Scott at (866) 326-5057 or email gjohnson@scott-scott.com to discuss their legal rights.
ESPR: 16.90 (+0.96)

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Esperion Therapeutics, Inc. (ESPR) and Lead Plaintiff Deadline: March 14, 2016
ACCESSWIRE - Mon Mar 07, 9:01AM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors of class action against Esperion Therapeutics, Inc. (Esperion or "the Company"

(NASDAQ: ESPR) and certain of its officers. The class action was filed in the United States District Court for the Eastern District of Michigan on behalf of a class consisting of all persons or entities who purchased shares from August 18, 2015 through September 28, 2015, all dates inclusive (the "Class Period"

. Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
ESPR: 16.90 (+0.96)

Hagens Berman Reminds Esperion Therapeutics, Inc. (NASDAQGM: ESPR) Investors of March 14, 2016 Lead Plaintiff Deadline
GlobeNewswire - Mon Mar 07, 7:30AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts Esperion Therapeutics, Inc. (NASDAQ:ESPR) investors there is a March 14, 2016 lead plaintiff deadline in the securities fraud class action lawsuit filed against the Company related to the delayed approval of Esperion's leading cholesterol drug.
ESPR: 16.90 (+0.96)

SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Esperion Therapeutics, Inc.
BusinessWire - Fri Mar 04, 8:15PM CST
Law Office of Brodsky & Smith, LLC announces an investigation of Esperion Therapeutics, Inc. ("Esperion" or the "Company"

(Nasdaq: ESPR) for potential violations of federal securities laws and breaches of the Esperion Board's fiduciary duties.
ESPR: 16.90 (+0.96)

SECURITIES NOTICE: Rosen Law Firm Reminds Esperion Therapeutics, Inc. Investors of Important March 14, 2016 Deadline in Class Action - ESPR
GlobeNewswire - Fri Mar 04, 2:30PM CST
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Esperion Therapeutics, Inc. securities (NASDAQ:ESPR) from August 18, 2015 through September 28, 2015, both dates inclusive (the "Class Period"

of the important March 14, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Esperion Therapeutics investors under the federal securities laws.
ESPR: 16.90 (+0.96)

INVESTOR ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Lawsuit Involving Esperion Therapeutics, Inc. and a Lead Plaintiff Deadline of March 14, 2016 - ESPR
GlobeNewswire - Fri Mar 04, 11:04AM CST
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Michigan on behalf of investors who purchased Esperion Therapeutics, Inc. (NASDAQ:ESPR) securities between August 18, 2015 and September 28, 2015.
ESPR: 16.90 (+0.96)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thunes, UnionPay Revamp China Payments with $10K Daily

Unveiling a New Era for Cross-Border Payments Thunes is shaking things up, unleashing a fresh wave of possibilities for moving money into China's mainland. In a strategic twist, Thunes has teamed up with UnionPay International, aiming to transform the cross-border payment experience. With a potent combo of bank-grade security and hefty daily transaction limits, this...

Orthocell's Remplir™ Hits Record U.S. Sales in October

Orthocell's October Surprise with Remplir™ Sales Well, isn't this a breath of fresh air? Orthocell Limited just reported a staggering rise in its U.S. Remplir™ sales for October 2026. We're talking 92 units shifting off the shelves, pulling in a tidy AU$279,000. That's an 84% leap compared to the average monthly sales of 50 units in Q1 FY27. It seems the company's...

RD Technologies Ramps Up Cross-Border Payments

RD Technologies: Revving Up the Payment Game RD Technologies is at it again, jazzing up its game in the cross-border payments realm. One can almost smell the digits doing a tango across continents—particularly as Hong Kong's financial warriors set their sights on beefing up trade between Africa and Asia. New Alliances in the Payment Arena Here's a roadmap: Connect the...

Extend Your Water Heater's Life with Anode Care

Small Component, Big Impact: The Anode Rod Picture this: You’ve got a trusty water heater keeping your showers steamy, but lurking inside is a villain called rust. Enter the unsung hero—the anode rod. It might not be glamorous, but this little piece of metal works overtime to save your tank from a watery grave. Tim Fessler and Dave Super, seasoned plumbing hotshots...

Roof Flashing Insights with Expert Jeremiah Lightsey

Why Flashing Is the Backbone of a Leak-Free Roof Ever wonder why some roofs just seem to withstand the wrath of Mother Nature better? The answer, my friends, often boils down to a little unsung hero: roof flashing. Our roof parts aren't exactly playing an even game; you've got chimneys, walls, skylights, just asking for trouble. That's where flashing steps in like an...

Gildan Faces Class Action Deadline Over Fraud Claims

Gildan's Legal Storm: Fraud Allegations When news hits about a big player like Gildan Activewear (NYSE: GIL) facing a class-action lawsuit, it's like a thunderstorm for investors who traded their stocks between February 19, 2025, and June 15, 2026. This lawsuit alleges what we some might call classic financial engineering—channel stuffing to be precise—that’s got...

Mastering Progressive Overload: Break Workout Plateaus

Getting off the Fitness Merry-Go-Round You've been hitting the gym, feeling great, and suddenly—bam! You've hit a wall so hard you might as well be a bug on a windshield. That's where our buddy Joshua Bankes comes in, explaining the magic of progressive overload for fitness buffs. Understanding Plateau Phenomena Remember, results aren't linear. As you start a new...

Perion Acquisition: Affle's Bold Leap in Ad Tech

Affle's Strategic Acquisition of Perion Jumpin' through another hoop, Affle is gearing up to snag Perion in a hefty deal valued at about $420 million. For those of you not knee-deep in the ad tech sandbox, Affle—trading on the NSE as AFFLE—is aiming to ramp up its AI-driven conversion game by absorbing Perion, a veteran in the omnichannel advertising realm. "This...

TESSAN and Jamie Leibert's Daring Alpine Documentary Launch

Steps Beyond the Obvious Adventure Launching headlong into the unknown—literally and figuratively—is what the documentary Jump Into The Unknown captures. TESSAN and Jamie Leibert have peeled back the curtain on adventure, showing us that it’s not just about the destination, but every twist, turn, and recalibrated step in between. The Backstory Behind Every Jump...

Potatoes vs. Candy: Halloween's Spuddy Surprise

When Halloween rolls around, you expect rabid kids clamoring for candy corn and chocolate bars. But this year, Idaho threw a spud into the sweets machine. Idaho's Potatoes Steal the Show In an unexpected twist, the Idaho Potato Commission ran a zany experiment on Halloween: kids had to choose between their beloved Halloween candy and a genuine Idaho potato. Imagine the...